Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of SVG101 vs Afinitor in Healthy Adults
NCT05490095Phase 1Completed
- Sponsor
- SoVarGen
- Start
- Jul 2021
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of everolimus in breast cancer, neuroendocrine tumors (NETs), renal cell carcinoma (RCC) and 1 more (2 arms), sponsored by SoVarGen. Primary endpoints: Area Under the Curve to Infinity up to 144 hours, Maximum Concentration up to 144 hours and 6 more. Started Jul 2021; status: completed.
02
Drugs
everolimus
03
Conditions
breast cancerneuroendocrine tumors (NETs)renal cell carcinoma (RCC)tuberous sclerosis complex (TSC)
Beyond the preview
Go deeper on NCT05490095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05490095.